Literature DB >> 33281038

Identification of Novel Diagnostic Biomarkers in Breast Cancer Using Targeted Metabolomic Profiling.

Nejc Kozar1, Kristi Kruusmaa2, Marko Bitenc3, Rosa Argamasilla3, Antonio Adsuar3, Iztok Takač4, Darja Arko4.   

Abstract

INTRODUCTION: Breast cancer (BC) is the most common cancer in women, with a high disease burden, especially in the advanced disease stages. Our study investigated the metabolomic profile of breast cancer patients' serum with the aim of identifying novel diagnostic biomarkers that could be used, especially for early disease detection.
MATERIALS AND METHODS: Using targeted metabolomic serum profiling based on high-performance liquid chromatography mass spectrometry, women with BC (n = 39) and a control group (n = 21) were examined for 232 endogenous metabolites.
RESULTS: The top performing biomarkers included acylcarnitines (ACs) and 9,12-linoleic acid. A combined panel of the top 4 biomarkers achieved 83% sensitivity and 81% specificity, with an area under the curve (AUC) of 0.839 (95% confidence interval, 0.811-0.867). Individual markers also provided significant predictive values: AC 12:0, sensitivity of 72%, specificity of 67%, and AUC of 0.71; AC 14:2, sensitivity of 74%, specificity of 71%, and AUC of 0.73; AC 14:0: sensitivity of 67%, specificity of 81%, and AUC of 0.73; and 9,12-linoleic acid, sensitivity of 69%, specificity of 67%, and AUC of 0.71. The individual markers, however, did not reach the high sensitivity and specificity of the 4-biomarker combination.
CONCLUSION: Using mass spectrometry-targeted metabolomic profiling, ACs and 9,12-linoleic acid were identified as potential diagnostic biomarkers for breast cancer. Additionally, these identified metabolites could provide additional insight into cancer cell metabolism.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  9,12-linoleic acid; Acylcarnitines; Breast cancer; Mass spectrometry; Metabolomic profiling

Mesh:

Substances:

Year:  2020        PMID: 33281038     DOI: 10.1016/j.clbc.2020.09.006

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  3 in total

1.  Single-Nucleotide Polymorphisms Promote Dysregulation Activation by Essential Gene Mediated Bio-Molecular Interaction in Breast Cancer.

Authors:  Xue Wang; Zihui Zhao; Xueqing Han; Yutong Zhang; Yitong Zhang; Fenglan Li; Hui Li
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

2.  Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints.

Authors:  Yida Huang; Shaoqian Du; Jun Liu; Weiyi Huang; Wanshan Liu; Mengji Zhang; Ning Li; Ruimin Wang; Jiao Wu; Wei Chen; Mengyi Jiang; Tianhao Zhou; Jing Cao; Jing Yang; Lin Huang; An Gu; Jingyang Niu; Yuan Cao; Wei-Xing Zong; Xin Wang; Jun Liu; Kun Qian; Hongxia Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-18       Impact factor: 12.779

3.  Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients.

Authors:  Judith Buentzel; Henry Gerd Klemp; Ralph Kraetzner; Matthias Schulz; Gry Helene Dihazi; Frank Streit; Annalen Bleckmann; Kerstin Menck; Darius Wlochowitz; Claudia Binder
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.